Prana Biotech : Unfassbarer Kaufdruck - 500 Beiträge pro Seite

[SOM.you.]

RE: Prana Biotech ( 922 196 )

Prana Biotech wird gerade entdeckt. Die australische Biotechschmiede befindet sich weiter auf dem Vormarsch.
Kurs aktuell 0,63 AUD.

Mit den SChwerpunkte im Bereich der Cretzfeldt-Jakob-Desease
setzt die Aktie gerade zu einem Höhenflug an.

Das beste :
Marktkaptalisierung aktuell ca. 6 Mio Euro. (!)
Nasdaq Listing ist für das erste HJ 2001 geplant.
Wer in Deutschland die begehrten STücke bekommt kann sich glücklich schätzen.



SOM

[SOM.you.]

RE: Prana Biotech

ok, ich bin wohl immernoch der einzige Deutsche der Investiert ist , aber ok :

Prana Biotech setzt den positiven Trend zum Mittag in Sydney fort.

Kurs aktuell : 0,72 AUD (+ 15 %)


SOM

[SOM.you.]

RE: Prana

0,74 AUD


SOM

[SOM.you.]

RE: Prana Biotech

Schlußkurs heute : 0,70 AUD

Ok, war mein letztes Posting in diesem Thread.
Vorbeugende Medikamente zum CFS stehen wohl bei zu wenigen auf der Tagesordnung.


SOM

[SOM.you.]

RE: Prana Biotech

wen es interessiert :

Prana Biotech zieht weiter an auf : 0,81 AUD

Ad Hoc :

PBT - ASX Company Announcement
13 November 2000
Part 1/1
--------
PRANA BIOTECHNOLOGY LIMITED
---------------------------

HOMEX - Melbourne
-------------------------
Scientist`s discovery of potential treatment for Alzhiemers

SCIENTIST PRESENTED LINK TO AN EXISTING DRUG FOR ALZHIEMER`S DISEASE
AT THE SOCIETY FOR NUEROSCIENCE

Prana Biotechnology Limited (ASX: PBT) today announced that Dr Ashley
Bush`s, (MD PhD), scientific advisor to Prana, today presented his
discovery of a potential treatment for Alzheimer`s Disease at the
annual meeting of the Society for Neuroscience in New Orleans.

Dr Bush said the drug, called Clioquinol, was approved for human human use
decades ago. Clioquinol is now being tested on 36 Alzheimer`s
patients. The patients are all moderately affected by Alzheimer`s
disease, but still live independently and are able to give informed
consent. The results of the test will not be known for at least
another 12 months. Patients are being carefully monitored for any
possible side effects.

Clioquinol was last used during the 1970s, when it was linked to a
rare neurological disorder that was found only in Japan, Dr Bush said
at the neuroscience meeting. "The syndrome appears due to rapid B12
depletion," Dr Bush added. "Now that we know what causes that side-
effect, we believe that we can prevent it, and rehabilitate the drug
for safe use once more".

Mice used in the initial experiment were genetically manipulated to
over-produce beta-amyloid, which creates the sticky plaques that are
a major feature of Alzheimer`s. Copper and zinc "decorate" those
plaques - and mice given Clioquinol, which strips away those metals,
showed a 51 percent reduction in the plaques compared with untreated
mice of the same strain.

"The drug was effective in the mice experiments not because it kills
germs but because it binds two metals," Dr Bush pointed out. "In a
third of the younger animals, it eliminated the plaques, even though
the animals continued to overproduce beta-amyloid."

Dr Bush believes that "the brain may heal and repair the damage -
depending on how advanced the disease is - if you get the plaque out
of the way."

Dr Bush and his colleagues are investigating ways to optimize the
effect of the drug, and determine the minimum and maximum safe
dosages. Currently, clinical trials have begun at the University of
Melbourne in Australia, headed by Colin Masters, MD, and sponsored by
Prana Biotechnology, Ltd. Professor Masters is a Director of Prana
Biotechnology and chair of the Company`s Scientific Advisory Board.

Dr Bush is the Director of the Laboratory for Oxidation Biology in
the Genetics and Aging Unit at Massachusetts General Hospital,
Associate Professor of Psychiatry at Harvard Medical School, and
Visiting Professor at the University of Melbourne. His discoveries
relating to the role of metals and oxidative stress in neurological
disorders have opened a new field of research of neuroscience that
forms the basis of the Company`s platform technology in the arena of
age-related diseases.

Dr Bush is a consultant on the scientific advisory board and
shareholder in Prana Biotechnology, which had sponsored the research
at MGH until September 1999.

ABOUT PRANA BIOTECHNOLOGY LIMITED

For more information, please visit the Company`s website at
http://www.pranabio.com.


Greets


SOM

[a.head]

Falsches Forum!

[SOM.you.]

RE: Prana Biotech

jetzt : 1,031 AUD


SOM

[SOM.you.]

RE: Prana Biotech

jemand drin ?


SOM

[kundekay]

Immer noch.Es scheint ja langsam Bewegung rein zu kommen. In AU 1,10(10%), NAsdaq 0,61(12,96%) bei 210.000 Stück. die nächste woche wird interessant. Hast du news?
KK

[kundekay]

sorry, die jungs da unten waren noch garnicht fertig.
Schluß(3:55pm) 1,26 AUD (+26% Tageshoch und 52-Wochenhoch!) bei 711.912 Volumen

[wizcom7]

Habe ich heute geschickt bekommen! Ich bin fett in Prana investiert!!!!!!! Was meint Ihr ist das schon der Durchbruch?


FOR IMMEDIATE RELEASE



PRANA’S SCIENCE REVERSED ALZHEIMER’S IN MICE

Findings Published in Neuron

Melbourne, Australia - June 22, 2001 - The prestigious scientific journal
Neuron released today scientific findings by Harvard based scientist Ashley
I. Bush, MD PhD., chief scientific advisor to Prana Biotechnology Ltd. (OTC:
PRNAF, ASX: PBT), and the Mental Health Research Institute, University of
Melbourne, show that a new drug could provide the first successful treatment
of the underlying biological cause of Alzheimer’s disease (AD).
In the article, Dr. Bush reports that Clioquinol, a Copper/Zinc-binding drug
that is given orally to transgenic mice and Prana’s lead compound, markedly
reduced their Alzheimer brain pathology within nine weeks; decreasing
beta-amyloid accumulation by 50 percent during that period. This article
comes after years of research conducted by Dr. Bush and his colleagues at
Massachusetts General Hospital, Harvard Medical School, and the Mental
Health Research Institute of Victoria, University of Melbourne. The focus
of their discovery highlights the unique binding attributes of the
beta-amyloid (A?) protein with zinc and copper. This breakthrough provides
a viable explanation for the abnormal binding of these metals with A? that
is commonplace in AD. This reaction ultimately leads to the corruption of
the protein and its ensuing toxicity. Copper and Zinc are normally present
at high concentrations in the regions of the brain that are most affected by
AD damage.
Prana Biotechnology Executive Chairman Geoffrey Kempler commented, “Neuron’s
publication of the research findings is dramatic testimony to the validity
of Dr. Bush’s scientific work on AD. It was very pleasing that the results
were reported in a major article in the Wall Street Journal this morning.”
Mr. Kempler further pointed out that Clioquinol is only one of a number of
Prana compounds aimed at a range of neurological diseases including
Alzheimer’s disease; Parkinson`s disease; Creutzfeldt-Jakob disease (CJD or
Mad Cow disease) and Motor Neuron disease. Prana is also developing
diagnostic tests for additional conditions.
Clioquinol is currently in a phase two clinical trial at the Mental Health
Research Institute and is supported by Prana Biotechnology Ltd. and the
Alzheimer`s Association of America. The Company anticipates results from
the double blind study to be available in the early part of 2002.
-more-

About Alzheimer`s disease
Alzheimer`s disease is a progressive neurodegenerative disease that slowly
destroys nerve cells in the brain. Overall, most investigators in the field
attribute the cause of AD to the accumulation of a protein called
beta-amyloid within the brain. There has been no agreement however, on what
causes the accumulation or how the A? is associated with the loss of brain
function that leads to memory loss and dementia. The disease primarily
afflicts people over the age of 65 and is growing rapidly. Currently, in
the United States, AD affects approximately four million Americans.
About Neuron
Neuron is the most prestigious scientific journal in the world dealing with
neuroscience. Out of approximately 2,700 scientific journals in the world,
Neuron would be considered in the top ten. Dr. Bush’s article is also
available on Neuron website at www.neuron.org <http://www.JBC.org>.
About Prana Biotechnology Limited
Based in Australia, incorporated in 1997 and listed on the Australian Stock
Exchange in March 2000, Prana Biotechnology (OTC: PRNAF; ASX: PBT) was
established to commercialize research into Alzheimer`s disease and other
major age-related degenerative disorders. Its mission is to develop
diagnostic and therapeutic drugs to treat the central disease pathways that
cause degeneration of the brain as the aging process progresses. Prana`s
technology has emerged from its researchers at prominent international
institutions such as Massachusetts General Hospital at Harvard Medical
School and the University of Melbourne. For further information, please
visit our web site at www.pranabio.com <http://www.pranabio.com>.

###
For more information contact:
Company Investor Media
Geoffrey Kempler Conrad F. Mir Rudi Michelson
Prana Biotechnology Limited The Anne McBride Company Monsoon Communications
[phone]-983-1702 ext. 209 03 9620 3199
[e-mail] [e-mail] [e-mail]


This press release contains “forward looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995 regarding the
Company’s business strategy and future plans of operation. Forward-looking
statements involve known and unknown risks and uncertainties; both general
and specific to the matters discussed in this press release. These and
other important factors, including those mentioned in various Securities and
Exchange Commission filings made by the Company, may cause the Company’s
actual results and performance to differ materially from the future results
and performance expressed in or implied by such forward-looking statements.
The forward-looking statements contained in this press release speak only as
of the date hereof and the Company expressly disclaims any obligation to
provide public updates, revisions or amendments to any forward-looking
statements made herein to reflect changes in the Company’s expectations or
future events.

[kundekay]

da glaubt doch tatsächlich einer noch welche für 0,45Euro in Berlin zu kriegen.
@SOM.you bist du das?
Ich hab u.a. ne Order für 0,55 stehen, selbst das wär noch günstig
kk

[SOM.you.]

RE: Prana Biotech

nee, das bin ich nicht.
Mit 11.000 Optionsscheinen und 5.000 Aktien bin ich drin.

Aber in Berlin sind nach meinem Orderbuch noch 2 Verkäufer im Markt.

1.) 0,60 Euro 300 Stücke
2.) 0,73 Euro 2300 Stücke

dafür,daß der faire Wert nach Schlußkurs bei 0,78 Euro liegt eigentlich ein Schnäppchen.

Ich hol mir mal die für 0,60.


SOM

[ThomASAC]

WKN ?? TOM

[SOM.you.]

RE: WKN

937103


SOM

[kundekay]

hab auch gerade noch das mail von frau elisabeth corcoran bekommen. hört sich sehr gut an oder was meint ihr?
kk (und nochmal schönes wochenende)

[SOM.you.]

RE: Prana Biotech

ganz lustig, in Berlin gibt es immernoch die Papiere rund 6 % günstiger als in Sydney.

0,73 AUD statt 0,77 AUD.

Wenn keiner will kaufe ich mir die shares.


SOM

[SOM.you.]

RE: Prana

nanu jetzt noch ne Kauforder im Markt über 10.000 Stücke.
hat sonst keiner Einblick ins Orderbuch Berlin ?

SOM

[Snoopy28]

Wo bekommt man denn die Einsicht in die Orders?

[Bombenleger]

Wer kann mir sagen wie hoch die Marktkapitalisierung ist?

[SOM.you.]

RE: Prana Biotech

1.) Buy Empfehlung von CIBC World Markets mit dem Hinweis : high Risk

2.) Marktkapitalisierung : rd. 72 Mio AUD bei 57,2 Mio shares outstanding (also rd. 45 Mio Euro )

3.) Der Verkäufer in Berlin hat seine Order zu 0,73 Euro zurückgenommen. Ist wahrscheinlich gerade von der Arbeit gekommen, und hat mal nachgerechnet.


weitere Infos bei www.pranabio.com

Greets

SOM

[SOM.you.]

RE: Prana Biotech

ein Manager der Prana Biotech kauft weiterhin kräftig
Call-Options auf die Aktie.

AdHoc von Heute :

HOMEX - Melbourne

+++++++++++++++++++++++++
NOTICE OF DIRECTOR`S INTERESTS
Section 205G of the Corporations Law


UPDATING NOTICE

Name of Director Brian Meltzer

Name of Company Prana Biotechnology

Date of Last
Notification to ASX At Float 23/03/2000

Date Director`s
Interest Changed 11/07/2001


I have a relevant interest in the following securities of the
company or related bodies corporate:

Type of security: Options
Number of securities: 10,000

Purchase of 10,000 additional options in Prana on 11/07/2001


SOM

[SOM.you.]

RE: Prana

die Kurse zeigten sich freundlicher
sowohl Aktien als auch der OS konnte zulegen.

1,17 AUD für die Aktie
0,75 AUD für den OS

Prima !

Somit liegt der faire Kurs der Aktie aktuell bei 0,70 Euro.

SOM

[kundekay]

@SOM.you

sieht nicht schlecht aus. Nur leider wird hier in Berlin nicht gehandelt. Gib mir doch bitte kurz einen Überblick, wie ich in AUS ordern kann.(Bin bei comdirect)Würde gern noch ein paar nachlegen.

KK

[kundekay]

@all
bei der monentanen Entwicklung im Biotech-Bereich vielleicht ganz interessant:
Performance Prana Biotech:
1 Woche + 6,56%
1 Monat + 30,00%
1 Jahr + 116,67%
Quelle:onvista.de

@SOM.you
ich warte immer noch auf die infos zum ordern in AUS.
danke
kk

[SOM.you.]

RE: Prana

@kundekay
bei der CD geht das nur telefonisch.
Das letzte Mal haben die meine Australien Order in die Schweiz geroutet. War aber dann kein Problem, weil die CD Ihren Fehler schnell selbst erkannt haben.

Und wie immer nur Limitiert Ordern.


SOM

[kundekay]

Habe heute eine Mail von KAte Mazoudir erhalten, die ich leider nicht öffnen kann. Im Betreff steht etwas von einer ZUsammenarbeit mit dem General Hospital/HArvard. Kann jemand der sie auch bekommen hat mal den Inhalt hier reinstellen?
Danke KK

[kundekay]

Habe heute eine Mail von KAte Mazoudir erhalten, die ich leider nicht öffnen kann. Im Betreff steht etwas von einer ZUsammenarbeit mit dem General Hospital/HArvard. Kann jemand der sie auch bekommen hat mal den Inhalt hier reinstellen?
Danke KK

[kundekay]

Und wieder eine MAil von Kate. was meint ihr dazu?

PRANA BIOTECHNOLOGY FILES PATENT LAWSUIT

Melbourne, Australia - September 28, 2001 - Prana Biotechnology Limited
(NASDAQ: PRNAF; ASX: PBT), the Australian biotechnology company, initiated a
lawsuit on September 26, 2001 in the United States District Court for the
District of Columbia against Greek-based company P.N. Gerolymatos S.A and
Dr. Panayotis N. Gerolymatos seeking, among other things, to establish two
members of Prana`s Scientific Advisory Board, Ashley Bush, M.D., Ph.D.,
Director of the Laboratory for Oxidation Biology, within the Genetics of
Aging Unit at Massachusetts General Hospital and Associate Professor in the
Department of Psychiatry at Harvard Medical School, Rudolph E. Tanzi, Ph.D.,
Professor of Neurology at Harvard Medical School and Director of
Massachusetts General Hospital’s Genetics and Aging Unit, and Dr. Robert A.
Cherney, Senior Research Officer at the Department of Pathology University
of Melbourne at the Mental Health Research Institute as inventors of two
United States patents.

The lawsuit also seeks to establish Prana`s ownership rights in the patents.
Prana is represented by the law firm Hale and Dorr, LLP.

Prana Biotechnology is developing a pipeline of drugs for the diagnosis and
treatment of Alzheimer`s disease and other neurodegenerative disorders.
About Prana Biotechnology Limited
Based in Australia, incorporated in 1997 and listed on the Australian Stock
Exchange in March 2000, Prana Biotechnology (NASDAQ: PRNAF; ASX: PBT) was
established to commercialize research into Alzheimer`s disease and other
major age-related degenerative disorders. Its mission is to develop
therapeutic drugs to treat the central disease pathways that cause
degeneration of the brain and eyes as the aging process progresses. Prana`s
technology has emerged from its researchers at prominent international
institutions including Massachusetts General Hospital, a teaching hospital
of Harvard Medical School, and the University of Melbourne. For further
information, please visit our web site at www.pranabio.com

[SOM.you.]

RE: PBT

weiter halten.
Erfolge kommen frühestens in einem Jahr.


SOM

[ankii]

@all,

gibt es Neuigkeiten, auf jeden Fall tut sich was im Kurs.

[SOM.you.]

RE: Prana Biotech

leider bin ich aus dieser Aktie schon raus.

Nach einigen 100 % realisiertem Kursgewinn mit den Prana Optionsscheinen.
Grummel. die Optionsscheine habe ich damals zu 0,17 AUD gekauft, und dann Häppchenweise über 0,60 AUD veräussert.
Etwas zu früh, wie sich jetzt zeigt. Die Prana OS liegen aktuell bei 1,06 AUD !

Trotzdem läuft die Aktien weiter, in erster Linie in Australien.

Phase II Ergebnisse sollen im April folgen.
Prana ist zur Zeit genau so chancenreich wie riskant.

Prana Biotech notiert in Sydney auf Alltime Hogh bei 1,60 AUD.


SOM

[SOM.you.]

RE: Prana



hier mal das Logo für alle Prana Fans.

zu den Boardmail Anfragen :
aktuell bin ich in folgenden Biotechs investiert:

Bio-Rad
KK 30,50 US$ aktuell 67,25 (ATH)
SL-Marke : 58,90 US$



Agenix
KK 0,15 Euro aktuell 0,29 Euro (ATH)
ohne SL_Marke




SOM